American Society of Clinical Oncology Annual Meeting (ASCO) | Conference

Meric-Bernstam, MD, Discusses Pertuzumab Plus Trastuzumab Use Across HER2-Positive Solid Tumors
August 05, 2021

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.

Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer
June 08, 2021

Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, according to data from the 2021 ASCO Annual Meeting.

Larotrectinib Is Efficacious and Tolerable in NTRK-Fusion Positive CNS Tumors
June 07, 2021

Data from 2 clinical trials proved that larotrectinib is efficacious and safe in treating adults and children with NTRK fusion-positive central nervous system cancers.

Pediatric Patients With RET-Altered Tumors Experience Tumor Responses With Selpercatinib
June 07, 2021

Evidence of preliminary activity was noted with the use of the RET inhibitor selpercatinib in pediatric patients with solid tumors harboring RET alterations.

MAPK Expression Does Not Drive Selumetinib Response in Refractory Pediatric and AYA Cancers
June 05, 2021

While selumetinib was well-tolerated, it did not drive objective responses.

Zenocutuzumab Highly Effective in Treating Variety of Pretreated NRG1+ Cancers
June 05, 2021

For patients with NRG1 fusion–positive cancers, zenocutuzumab represents a promising novel targeted therapeutic option.

SHP2 Inhibition With TNO155 for Advanced Solid Tumors Shows Initial Safety, Favorable Pharmacokinetic Data
June 04, 2021

The phase 1 dose-finding CTNO1552101 trial of TN0155 in adults with advanced solid tumors reported initial results at the 2021 ASCO Annual Meeting.

Expert Looks Forward to Potentially Practice-Changing Presentations at ASCO 2021
June 03, 2021

CancerNetwork® sat down with Alison Schram, MD, to discuss her thoughts on research with the greatest potential to positively influence patient care being presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Worse Survival Noted for Patients With Cancer Treated in States With Lower Medicaid Eligibility Limits
May 20, 2021

Based on outcomes from a study involving patients with cancer, Medicaid may benefit from expansion in certain areas where eligibility limits hinder adequate coverage.

Younger African American Men With Prostate Cancer Show Improved Outcomes With More PSA Screenings
May 20, 2021

Prostate cancer in African American men was improved with higher rates of screening for prostate-specific antigen.